Supplementary Materials

Supplementary Material for:

A small-molecule antivirulence agent for treating Clostridium difficile infection

Kristina Oresic Bender, Megan Garland, Jessica A. Ferreyra, Andrew J. Hryckowian, Matthew A. Child, Aaron W. Puri, David E. Solow-Cordero, Steven K. Higginbottom, Ehud Segal, Niaz Banaei, Aimee Shen, Justin L. Sonnenburg, Matthew Bogyo*

*Corresponding author. E-mail: mbogyo{at}stanford.edu

Published 23 September 2015, Sci. Transl. Med. 7, 306ra148 (2015)
DOI: 10.1126/scitranslmed.aac9103

This PDF file includes:

  • Materials and Methods
  • Fig. S1. TcdB-induced cell rounding in HFF cells.
  • Fig. S2. Efficacy of TcdB inhibitors in biochemical and cell-based assays.
  • Fig. S3. Ebselen protects cells against TcdB-induced toxicity in vitro.
  • Fig. S4. Ebselen inhibits toxin-induced cytopathic effect in a fecal sample from a C. difficile patient.
  • Fig. S5. Effect of ebselen on the GTD domain of TcdB.
  • Fig. S6. Ebselen protects against autoprocessing of full-length wild-type and L543A toxin over time.
  • Fig. S7. Dose-response plots showing the activity of TcdB in feces of vehicle- and ebselen-treated mice from days 1 to 4 after C. difficile infection.
  • Table S1. List of TcdB CPD inhibitors with corresponding IC50 values obtained from the fluorescence polarization high-throughput screen.
  • Table S2. Primary data supporting Fig. 4E.
  • Table S3. Primary data supporting Fig. 4F.
  • Table S4. Primary data supporting Fig. 5 (D and E).
  • Table S5. Primary data supporting Fig. 6C.
  • References (6064)

[Download PDF]